{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006482","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.166539+00:00","generated_at":"2026-05-22T12:23:47.106383+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Voyager Q1 2025 net loss $31.0M, revenue down 67% YoY; cash $295M into mid-2027","bullets":["Net loss $31.0M vs $11.3M YoY; collaboration revenue $6.5M vs $19.5M YoY (−67%).","Cash, cash equivalents & marketable securities $295M; expects runway into mid-2027.","R&D expenses $31.5M (+16% YoY); G&A $9.6M (+12% YoY).","VY1706 tau silencing gene therapy achieved up to 73% tau mRNA knockdown in NHPs; IND/CTA filings expected 2026.","Neurocrine-partnered FA and GBA1 IND submissions on track for 2025; up to $35M milestone potential 2025-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006482","json":"https://secwatch.observer/filing/0001558370-25-006482.json","markdown":"https://secwatch.observer/filing/0001558370-25-006482.md","text":"https://secwatch.observer/filing/0001558370-25-006482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837025006482/0001558370-25-006482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837025006482/vygr-20250506x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:23:47.106383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}